AZ 03Alternative Names: AZ03; PDI 43
Latest Information Update: 19 Jul 2016
At a glance
- Originator Ache Laboratories
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hypertension
Most Recent Events
- 01 Jun 2012 Early research in Hypertension in Brazil (unspecified route) (Ache Laboratories Annual Report,